ATE470445T1 - Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) - Google Patents
Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads)Info
- Publication number
- ATE470445T1 ATE470445T1 AT08004276T AT08004276T ATE470445T1 AT E470445 T1 ATE470445 T1 AT E470445T1 AT 08004276 T AT08004276 T AT 08004276T AT 08004276 T AT08004276 T AT 08004276T AT E470445 T1 ATE470445 T1 AT E470445T1
- Authority
- AT
- Austria
- Prior art keywords
- ranolazine
- eads
- depolarization
- medication
- produce
- Prior art date
Links
- XKLMZUWKNUAPSZ-UHFFFAOYSA-N N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide Chemical compound COC1=CC=CC=C1OCC(O)CN1CCN(CC(=O)NC=2C(=CC=CC=2C)C)CC1 XKLMZUWKNUAPSZ-UHFFFAOYSA-N 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229960000213 ranolazine Drugs 0.000 title 1
- 208000018452 Torsade de pointes Diseases 0.000 abstract 2
- 208000002363 Torsades de Pointes Diseases 0.000 abstract 2
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000031352 familial ventricular tachycardia Diseases 0.000 abstract 1
- 208000012404 paroxysmal familial ventricular fibrillation Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
- 206010047302 ventricular tachycardia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37015002P | 2002-04-04 | 2002-04-04 | |
| US40829202P | 2002-09-05 | 2002-09-05 | |
| US42258902P | 2002-10-30 | 2002-10-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470445T1 true ATE470445T1 (de) | 2010-06-15 |
Family
ID=29255318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08004276T ATE470445T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) |
| AT03723907T ATE397932T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03723907T ATE397932T1 (de) | 2002-04-04 | 2003-04-04 | Verwendung von ranolazine zur herstellung eines medikaments zur behandlung von arrhythmien |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030220344A1 (de) |
| EP (3) | EP1490066B1 (de) |
| JP (1) | JP4608217B2 (de) |
| KR (2) | KR20100119804A (de) |
| CN (2) | CN101843619A (de) |
| AT (2) | ATE470445T1 (de) |
| AU (3) | AU2003230810B2 (de) |
| CA (1) | CA2481192C (de) |
| CY (1) | CY1110400T1 (de) |
| DE (2) | DE60321550D1 (de) |
| DK (2) | DK1490066T3 (de) |
| ES (2) | ES2304507T3 (de) |
| HK (1) | HK1120390A1 (de) |
| IL (1) | IL197406A0 (de) |
| MX (1) | MXPA04009637A (de) |
| NO (1) | NO330953B1 (de) |
| NZ (1) | NZ535610A (de) |
| PT (2) | PT1930007E (de) |
| SI (2) | SI1930007T1 (de) |
| WO (1) | WO2003086401A1 (de) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| JP4546824B2 (ja) * | 2002-05-21 | 2010-09-22 | ギリアード・パロ・アルト・インコーポレイテッド | 糖尿病を処置する方法 |
| KR20060124646A (ko) * | 2003-12-18 | 2006-12-05 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 1-아칸-2-올 치환된 피페라진 및 피페리딘 화합물 |
| MX2007005367A (es) * | 2004-11-09 | 2007-06-18 | Cv Therapeutics Inc | Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. |
| CN101098682A (zh) * | 2005-01-06 | 2008-01-02 | Cv医药有限公司 | 包括雷诺嗪的缓释药物制剂 |
| US20060264458A1 (en) * | 2005-05-03 | 2006-11-23 | Jie Du | Quinine dosage forms and methods of use thereof |
| US20080153840A1 (en) * | 2006-12-21 | 2008-06-26 | Luiz Belardinelli | Reduction of cardiovascular symptoms |
| EP2117550A1 (de) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Verwendung von ranolazin zur behandlung nicht-koronarer mikrovaskulärer erkrankungen |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| JP2010518169A (ja) | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 心血管疾患の処置のためのラノラジンの使用 |
| US20080248112A1 (en) * | 2007-02-13 | 2008-10-09 | Brent Blackburn | Use of ranolazine for the treatment of coronary microvascular diseases |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20080299195A1 (en) * | 2007-05-31 | 2008-12-04 | Brent Blackburn | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20090203707A1 (en) * | 2008-02-06 | 2009-08-13 | Sridharan Rajamani | Methods for treating pain |
| EP2337559A2 (de) * | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Zusammensetzung zur behandlung von vorhofflimmern mit amiodaron und ranolazin |
| US20100113514A1 (en) | 2008-10-30 | 2010-05-06 | Gilead Palo Alto, Inc. | Fused heterocyclic compounds as ion channel modulators |
| US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
| WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
| US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
| EP2847158A4 (de) | 2012-05-07 | 2015-12-30 | Cellix Bio Private Ltd | Zusammensetzungen und verfahren zur behandlung neuromuskulärer erkrankungen und neurodegenerativer erkrankungen |
| WO2013167985A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological disorders |
| US9403826B2 (en) | 2012-05-08 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory disorders |
| US9434704B2 (en) | 2012-05-08 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological degenerative disorders |
| US9266823B2 (en) | 2012-05-08 | 2016-02-23 | Cellix Bio Private Limited | Compositions and methods for the treatment of parkinson's disease |
| US9309233B2 (en) | 2012-05-08 | 2016-04-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of blood clotting disorders |
| WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
| US9499527B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of familial amyloid polyneuropathy |
| WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| WO2013168015A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of asthma and allergy |
| WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
| WO2013168004A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of fibromyalgia pain |
| US9233161B2 (en) | 2012-05-10 | 2016-01-12 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological conditions |
| WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| WO2013168000A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of severe pain |
| US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| WO2013168005A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
| US9499526B2 (en) | 2012-05-10 | 2016-11-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurologic diseases |
| US9273061B2 (en) | 2012-05-10 | 2016-03-01 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| CN104603097A (zh) | 2012-05-23 | 2015-05-06 | 塞利克斯比奥私人有限公司 | 用于治疗多发性硬化症的组合物和方法 |
| US9492409B2 (en) | 2012-05-23 | 2016-11-15 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
| WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
| CA2873104A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of mucositis |
| JP6202287B2 (ja) | 2012-05-23 | 2017-09-27 | セリックスビオ プライヴェート リミテッド | 炎症性腸疾患の治療のための組成物及び方法 |
| US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
| US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
| WO2014027262A2 (en) * | 2012-08-14 | 2014-02-20 | Mahesh Kandula | Compositions and methods for the treatment angina and cardiovascular conditions |
| US9624168B2 (en) | 2012-09-06 | 2017-04-18 | Cellix Bio Private Limited | Compositions and methods for the treatment inflammation and lipid disorders |
| WO2014037834A2 (en) | 2012-09-08 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of inflammation and lipid disorders |
| US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
| WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
| AU2014296145A1 (en) * | 2013-08-01 | 2016-01-28 | Gilead Sciences, Inc. | Compound and methods for treating long QT syndrome |
| US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
| WO2016110865A1 (en) | 2015-01-06 | 2016-07-14 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammation and pain |
| SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
| CN107207403A (zh) | 2014-09-29 | 2017-09-26 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的组合物和方法 |
| CN107108535B (zh) | 2014-10-27 | 2020-04-28 | 塞尔利克斯生物私人有限公司 | 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐 |
| US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
| US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
| US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
| US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
| US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
| US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
| US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
| US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
| US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
| KR101617683B1 (ko) * | 2015-01-09 | 2016-05-03 | 연세대학교 산학협력단 | 부정맥 치료제 효과 평가 시스템 및 방법 |
| TW201717919A (zh) | 2015-07-02 | 2017-06-01 | 國際藥品股份公司 | 雷諾多重壓縮錠劑 |
| WO2018001582A1 (en) | 2016-06-30 | 2018-01-04 | Interquim, S.A. | Ranolazine multiple compressed tablets |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4567264A (en) * | 1983-05-18 | 1986-01-28 | Syntex (U.S.A.) Inc. | Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ES2091211T3 (es) * | 1989-06-23 | 1996-11-01 | Syntex Inc | Ranolazina y piperazinas relacionadas utilizadas en el tratamiento de tejidos que sufren una lesion fisica o quimica. |
| JPH03141258A (ja) * | 1989-10-25 | 1991-06-17 | Kowa Co | 新規なピペラジン誘導体 |
| DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | Univ British Columbia | Aminocyclohexylester und ihre anwendung |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| MXPA02007639A (es) * | 2000-02-18 | 2004-08-23 | Cv Therapeutics Inc | Inhibidores de la oxidacion parcial de los acidos grasos en el tratamiento de la falla cardiaca congestiva. |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| EP1282436B1 (de) * | 2000-05-19 | 2008-06-11 | Amylin Pharmaceuticals, Inc. | Behandlung des akuten koronaren syndroms mit glp-1 |
| US20020052377A1 (en) * | 2000-07-21 | 2002-05-02 | Wolff Andrew A. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
-
2003
- 2003-04-03 US US10/406,894 patent/US20030220344A1/en not_active Abandoned
- 2003-04-04 KR KR1020107021063A patent/KR20100119804A/ko active IP Right Grant
- 2003-04-04 DE DE60321550T patent/DE60321550D1/de not_active Expired - Lifetime
- 2003-04-04 AT AT08004276T patent/ATE470445T1/de active
- 2003-04-04 AU AU2003230810A patent/AU2003230810B2/en not_active Ceased
- 2003-04-04 PT PT08004276T patent/PT1930007E/pt unknown
- 2003-04-04 KR KR10-2004-7015749A patent/KR20040099395A/ko not_active Application Discontinuation
- 2003-04-04 ES ES03723907T patent/ES2304507T3/es not_active Expired - Lifetime
- 2003-04-04 PT PT03723907T patent/PT1490066E/pt unknown
- 2003-04-04 DK DK03723907T patent/DK1490066T3/da active
- 2003-04-04 EP EP03723907A patent/EP1490066B1/de not_active Expired - Lifetime
- 2003-04-04 NZ NZ535610A patent/NZ535610A/en not_active IP Right Cessation
- 2003-04-04 JP JP2003583420A patent/JP4608217B2/ja not_active Expired - Fee Related
- 2003-04-04 AT AT03723907T patent/ATE397932T1/de active
- 2003-04-04 EP EP10002699A patent/EP2198866A1/de not_active Withdrawn
- 2003-04-04 WO PCT/US2003/010434 patent/WO2003086401A1/en active Application Filing
- 2003-04-04 CA CA2481192A patent/CA2481192C/en not_active Expired - Fee Related
- 2003-04-04 MX MXPA04009637A patent/MXPA04009637A/es active IP Right Grant
- 2003-04-04 DE DE60332975T patent/DE60332975D1/de not_active Expired - Lifetime
- 2003-04-04 SI SI200331842T patent/SI1930007T1/sl unknown
- 2003-04-04 CN CN200910171650A patent/CN101843619A/zh active Pending
- 2003-04-04 EP EP08004276A patent/EP1930007B1/de not_active Expired - Lifetime
- 2003-04-04 DK DK08004276.5T patent/DK1930007T3/da active
- 2003-04-04 CN CNB038078716A patent/CN100548300C/zh not_active Expired - Fee Related
- 2003-04-04 SI SI200331293T patent/SI1490066T1/sl unknown
- 2003-04-04 ES ES08004276T patent/ES2345573T3/es not_active Expired - Lifetime
-
2004
- 2004-11-03 NO NO20044783A patent/NO330953B1/no not_active IP Right Cessation
-
2008
- 2008-09-03 CY CY20081100948T patent/CY1110400T1/el unknown
- 2008-12-05 HK HK08113291.1A patent/HK1120390A1/xx not_active IP Right Cessation
-
2009
- 2009-03-05 IL IL197406A patent/IL197406A0/en unknown
- 2009-03-17 AU AU2009201065A patent/AU2009201065B2/en not_active Ceased
- 2009-09-09 US US12/556,417 patent/US20100004255A1/en not_active Abandoned
-
2011
- 2011-05-09 AU AU2011202135A patent/AU2011202135A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE470445T1 (de) | Verwendung von ranolazin zur herstellung eines medikaments zur behandlung von frühen nachdepolarisationen (eads) | |
| GB0223038D0 (en) | Therapeutic compounds | |
| ATE517658T1 (de) | Arrythmie-klassifizierung und therapiewahl | |
| GB0225474D0 (en) | Therapeutic agents | |
| WO2003102016A3 (en) | Amyloid peptide inactivating enzyme to treat alzheimer's disease | |
| ATE473728T1 (de) | Verwendung von fluoreszierenden perlylenverbindungen zur behandlung menschlicher haare | |
| Neganova et al. | Mechanisms of antioxidant effect of natural sesquiterpene lactone and alkaloid derivatives | |
| DE60222745D1 (de) | Verwendung von neurofilamentproteinen zur behandlung von tumoren | |
| NO20011244L (no) | Behandling av multippelt myelom samt myelom-indusert benresorpsjon ved anvendelse av integrin-antagonister | |
| DE69829202D1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
| UA85232C2 (ru) | Оксабиспидиновые соединения и их применение в лечении сердечных аритмий | |
| ATE288498T1 (de) | Methoden zur inhibierung von helicobacter pylori | |
| ATE451091T1 (de) | Kosmetisches peeling-verfahren unter verwendung von harnstoff | |
| ATE380551T1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson | |
| MXPA05011428A (es) | Metodo de tratamiento de fibrilacion atrial o trepidacion auricular. | |
| CO5170445A1 (es) | Nuevos compuestos morfinoides,su preparacion y utilizacion | |
| DE50213170D1 (de) | Verwendung eines Mittel zur Therapie der Herzhypertrophie | |
| WO2002062204A3 (en) | Methods for diagnosing and treating heart disease | |
| DE50012667D1 (de) | Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen | |
| ATE214923T1 (de) | Verwendung von (r)-verapamil als medizin zur behandlung von angina | |
| CY1115214T1 (el) | Η χρηση της ρανολαζινης για την παρασκευη ενος φαρμακου για την θεραπεια των αρρυθμιων | |
| ATE376914T1 (de) | Verwendung einer wässrigen lösung mit einem oder mehreren bifluoriden zur verbesserung des trocknungsprozesses von frischholz | |
| RU2002103549A (ru) | Способ лечения органических поражений центральной нервной системы эндолюмбальной трансплантацией фетальных клеток человека | |
| ATE335472T1 (de) | Verwendung von substituierten pyrazolen zur herstellung eines medikaments zur behandlung von allergien |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1930007 Country of ref document: EP |